ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near ...

Sleep apnea affects over 29 million Americans, with Obstructive Sleep Apnea (characterized by pauses in breathing during ...

The ResMed share price is having a tough start to the week. Is this a buying opportunity for investors? Let's find ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

Needham analyst Michael Matson has maintained their neutral stance on RMD stock, giving a Hold rating on January 29.Invest with Confidence: ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

Q2 2025 Management View CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended ...